| 摘要 |
The invention relates to the use of a new type of peptide antagonists at glutamate receptors and a subtype of glutamate receptors (NMDA (N-methyl-D-aspartate)) for the manufacture of a medicament to influence the glutamate receptor and the NMDA-receptor controlled cells such as neurons or glial cells in the central nervous system. |
